US generic drugmaker Impax Laboratories (Nasdaq: IPXL) has entered into a collaboration with contract research and manufacturing firm Tolmar for the development, supply and distribution of generic topical prescription drug products.
As part of the deal, Tolmar will supply up to nine currently approved and marketed products, and Impax’ generics division, Global Pharmaceuticals, will commercialize these products following a short transition period.
The approved and pending Abbreviated New Drug Application products are:
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze